These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 20042644

  • 1. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S, Adelman RA, Rizzolo LJ.
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [Abstract] [Full Text] [Related]

  • 2. Claudin-19 and the barrier properties of the human retinal pigment epithelium.
    Peng S, Rao VS, Adelman RA, Rizzolo LJ.
    Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1392-403. PubMed ID: 21071746
    [Abstract] [Full Text] [Related]

  • 3. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y, Klettner A, Roider J.
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [Abstract] [Full Text] [Related]

  • 4. Claudin-3 and claudin-19 partially restore native phenotype to ARPE-19 cells via effects on tight junctions and gene expression.
    Peng S, Wang SB, Singh D, Zhao PY, Davis K, Chen B, Adelman RA, Rizzolo LJ.
    Exp Eye Res; 2016 Oct; 151():179-89. PubMed ID: 27593915
    [Abstract] [Full Text] [Related]

  • 5. Claudins regulate gene and protein expression of the retinal pigment epithelium independent of their association with tight junctions.
    Liu F, Xu T, Peng S, Adelman RA, Rizzolo LJ.
    Exp Eye Res; 2020 Sep; 198():108157. PubMed ID: 32712183
    [Abstract] [Full Text] [Related]

  • 6. Effects of proinflammatory cytokines on the claudin-19 rich tight junctions of human retinal pigment epithelium.
    Peng S, Gan G, Rao VS, Adelman RA, Rizzolo LJ.
    Invest Ophthalmol Vis Sci; 2012 Jul 27; 53(8):5016-28. PubMed ID: 22761260
    [Abstract] [Full Text] [Related]

  • 7. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
    Deissler HL, Deissler H, Lang GK, Lang GE.
    Exp Eye Res; 2013 Oct 27; 115():162-71. PubMed ID: 23891860
    [Abstract] [Full Text] [Related]

  • 8. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture.
    Geisen P, McColm JR, King BM, Hartnett ME.
    Curr Eye Res; 2006 Sep 27; 31(9):739-48. PubMed ID: 16966147
    [Abstract] [Full Text] [Related]

  • 9. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec 27; 247(12):1601-8. PubMed ID: 19597740
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2011 Aug 27; 95(8):1151-6. PubMed ID: 21273213
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun 27; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 12. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL, Deissler H, Lang GE.
    Br J Ophthalmol; 2012 Jul 27; 96(7):1023-8. PubMed ID: 22539748
    [Abstract] [Full Text] [Related]

  • 13. Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells.
    Villarroel M, García-Ramírez M, Corraliza L, Hernández C, Simó R.
    Exp Eye Res; 2009 Dec 27; 89(6):913-20. PubMed ID: 19660451
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H, Sakamoto T, Shirasawa M, Yoshihara N, Otsuka H, Sonoda S, Hisatomi T, Ishibashi T.
    Retina; 2015 May 27; 35(5):1007-15. PubMed ID: 25627091
    [Abstract] [Full Text] [Related]

  • 16. Different Effects of Thrombin on VEGF Secretion, Proliferation, and Permeability in Polarized and Non-polarized Retinal Pigment Epithelial Cells.
    Terasaki H, Shirasawa M, Otsuka H, Yamashita T, Uchino E, Hisatomi T, Sonoda S, Sakamoto T.
    Curr Eye Res; 2015 Sep 27; 40(9):936-45. PubMed ID: 25310246
    [Abstract] [Full Text] [Related]

  • 17. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells.
    Kannan R, Zhang N, Sreekumar PG, Spee CK, Rodriguez A, Barron E, Hinton DR.
    Mol Vis; 2006 Dec 22; 12():1649-59. PubMed ID: 17200665
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct 22; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.